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A 38-year-old female patient with well-controlled type 2 diabetes mellitus treated with
canagliflozin underwent ureteral stent placement for obstructive renal calculi. Ten days
following ureteroscopy and ureteral stenting, she developed fevers and blood cultures
grew Candida glabrata (C. glabrata). The patient was successfully treated with an
extended course of broad-spectrum antibiotics and antifungal agents. The clinical
presentation of candidemia is indistinguishable from bacteremia resulting in delay in
diagnosis and treatment. Candiduria is commonly seen in patients with type 2 diabetes,
however it rarely leads to candidemia in an otherwise healthy person following a relatively
simple urologic procedure. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors act by its
glycosuric effect and further increases the risk of genitourinary candida infection. Urologic
procedures may lead to bloodstream entry of the genitourinary fungal organisms and
result in life-threatening fungemia. Our case emphasizes the importance of awareness
of the increased risk of potentially life threatening fungemia in patients using SGLT-2
inhibitors to avoid delay in diagnosis and treatment.
Keywords: candidemia, candiduria, sodium-glucose co-transporter 2 inhibitors, canagliflozin, diabetes mellitus,
ureteral stent

BACKGROUND
According to the most recent Centers for Disease Control and Prevention (CDC) data, ∼46,000
healthcare-associated candida infections occur in the United States each year (1). Invasive Candida
infections can be fatal, with a 30-day all-cause mortality of 30% and high rates of morbidity
(2). Although, there are at least 15 distinct Candida species, more than 90% of the invasive
diseases are caused by the five most common pathogens, C. albicans, C. glabrata, C. tropicalis, C.
parapsilosis, and C. krusei (3). SGLT-2 inhibitors are known to increase the incidence of urogenital
infections however, there have been no reported cases of invasive candidemia associated with
SGLT-2 inhibitor use. Although these agents can potentiate the urinary colonization of candida,
it is unknown whether this colonization is a preceding factor for the development of candidemia
following urologic procedures. With our literature review, we propose that patient with type 2
diabetes treated with canagliflozin could be at a higher risk of candidemia following urological
procedures like ureteral stent placement by bloodstream entry of the organism.
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stent was placed. Urine from the left renal pelvis and bladder were
cultured for a second time which grew C. glabrata susceptible to
Fluconazole. On the 4th day of admission, blood cultures from
both anaerobic and aerobic samples grew C. glabrata. Dilated
fundus examination was negative for fungal ocular involvement
and transthoracic echocardiogram was unremarkable for valvular
vegetations. Blood cultures after antifungal initiation remained
negative. She was eventually discharged on oral fluconazole
800 mg daily for 2 weeks and cefazolin 2 g every 8 h for 7 days.

A 38-year-old Caucasian female presented to the emergency
department with 3 days of left lower quadrant abdominal pain
rated 6/10 with radiation to the left lower back. She also
reported a high-grade fever (103◦ F) with associated nausea and
vomiting. She denied dysuria or hematuria. Medical history
was significant for well-controlled type II diabetes mellitus,
hypertension, and hyperlipidemia. She was taking canagliflozin
100 mg daily, lisinopril 20 mg daily, and atorvastatin 80 mg
daily. She has been on canagliflozin (SGLT-2 inhibitor) for
type 2 diabetes mellitus for 14 months prior to the current
presentation. She denied any history of urinary tract infections
or renal stones. On presentation, her blood pressure was 172/86
mmHg, heart rate 94 beats per minute and temperature 102◦ F.
BMI was 46.61 kg/m2 . Physical examination revealed tenderness
to palpation in the left lower quadrant and left flank. The
rest of the examination was unremarkable. Urinalysis (Table 1)
revealed pyuria, bacteriuria, and nitrites. Hemoglobin A1C
was 7.5% (59 mmol/mol). CT abdomen and pelvis without
contrast showed an obstructive 4–5 mm left distal ureteral stone
associated with mild hydroureteronephrosis. She was diagnosed
with obstructing nephrolithiasis complicated by pyelonephritis
and was empirically treated with intravenous ceftriaxone 1 gram
every 24 h. Cystoscopy with retrograde pyelography was done
and a left 6-French × 24 cm double-J ureteral stent was placed.
Placement was confirmed with fluoroscopy and cystoscopy.
Intraoperative urine cultures obtained from the left renal pelvis
and bladder showed no growth. She was discharged home on
cefdinir 300 mg twice a day for 14 days and tamsulosin 0.4 mg
daily for 30 days with a urology follow-up appointment in 2
weeks.
Ten days later, she presented again with intermittent lowgrade fever (100.5◦ F) and left flank pain. She was hypotensive
(96/58 mmHg), tachycardic (104 bpm) and febrile with
temperature of 102.8◦ F. Physical examination revealed severe
tenderness to palpation in the left lower quadrant extending
to the suprapubic area. Laboratory workup (Table 1) showed
worsening leukocytosis, pyuria, bacteriuria, positive urinary
nitrites, and small leukocyte esterase. A repeat CT scan of the
abdomen and pelvis with renal stone protocol confirmed the
position of the left ureteral stent and absence of previously
seen stone. She was diagnosed with sepsis secondary to acute
pyelonephritis in the setting of recent stent placement and
started on aggressive intravenous hydration and PiperacillinTazobactam. Urine culture from the day of admission grew
Klebsiella pneumoniae with >100 k CFU/ml however blood
cultures remained negative. Despite appropriate antibiotics, she
remained febrile even after 48 h. Two days later, the anaerobic
blood cultures became positive for C. glabrata. She was started
on intravenous micafungin 100 mg every 24 h and antibiotic
was narrowed down based on culture sensitivities. Repeat
cystoureteroscopy with retrograde pyelogram revealed partial
contrast uptake in the left kidney due to an impacted ureteral
stone in the mid ureter. The presence of fungal elements and
cloudy urine were also found in the left kidney. The previously
placed left ureteral stent was removed and a new double-J ureteral
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DISCUSSION AND REVIEW OF
LITERATURE
Canagliflozin, the first sodium-glucose co-transporter 2 (SGLT2) inhibitor introduced in the USA was FDA approved in March
2013. Since then, SGLT-2 inhibitors have become popular in
the management of type 2 diabetes mellitus as monotherapy
(in the event of metformin intolerance), dual, or triple therapy.
Although, it increases the incidence of urogenital infections,
there is no report of candidemia associated with its use. We
hereby discuss possible association of candiduria leading to
candidemia following urologic procedure in a patient with
diabetes on SGLT-2 inhibitors with current evidence from
literature.
Candiduria is frequently encountered among patients with
diabetes and is even higher in presence of certain underlying
risk factors like female gender, indwelling urinary catheter, prior
use of antibiotics, and acidic urine. However, it rarely results
in candidemia. Ang et al. analyzed 249 cases of candidemia
and reported 26 cases of candidemia originating from a urinary
source in a retrospective review. However, most of the patients
who developed candidemia from urinary source had some
underlying risk factors like urinary tract abnormalities (88%),
use of antibiotics within 1 week (85%), underlying malignancies
(73%), urinary tract obstruction (73%), and prior urologic
procedure within 2 weeks (73%), which put them at an increased
risk of fungemia (4). Other similar studies also have not found
any direct evidence of association between candiduria leading
to candidemia without any of the underlying high risk factors
(5–9). Candiduria, however is linked with increased mortality
and is therefore considered as an independent marker of higher
mortality (8, 10, 11). In a randomized control trial, Binelli
et al. however found that candida isolates from urine and blood
were different in 52% of patients with simultaneous candiduria
and candidemia implying alternate source (12). Patients with
diabetes are inherently at increased risk of candiduria due to
glycosuria, immune dysfunction associated with hyperglycemia,
and increased virulence of Candida (13, 14). Various studies have
found candida to be third or fourth most commonly isolated
organisms from the urine among hospitalized patients (7, 15, 16).
A cross-sectional study on 305 patient with type 2 diabetes in
an ambulatory setting showed presence of candiduria in 12.5%
of patients, majority (95%) being in female (17). Nosocomial
candiduria has even a higher prevalence ranging from 10 to 89%
(7). Apart from uncontrolled diabetes, female gender, old age,
presence of indwelling urinary catheter, prior use of antibiotics,
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TABLE 1 | Laboratory studies.
Test (Units)

References range

1ST admission

2ND admission

WBC count (k/uL)

3.7–10.3

7.4

12.1

Hemoglobin (g/dL)

11.2–15.7

13.8

13.6

Glucose level (mg/dL)

74-99

286

161

Urea nitrogen, blood (mg/dL)

7–21

9

9

Creatinine level (mg/dL)
Alanine aminotransferase (U/L)

0.60–1.10
8–33

0.69

0.60

43

41

Aspartate aminotransferase (U/L)

11–32

46

28

Alkaline phosphatase (U/L)

35–104

135

113

URINALYSIS WITH MICROSCOPY
Specific gravity
pH

1.001–1.030

≥1.030

1.025

4.5–8.0

5.0

5.0
≥300

Protein (mg/dL)

–

30

Glucose (mg/dL)

–

≥1,000

Negative

Ketone

–

Trace

Trace

Blood

–

Small

Large

Nitrite

–

Positive

Positive

–

Negative

Small

Leukocyte esterase
WBC (/HPF)

0–5

16–30

>50

RBC (/HPF)

0–3

3

>50

Bacteria

–

Present

Present

Culture

–

10,000–100,000 CFU/ml mixed
urogenital flora

>100,000 CFU/ml Klebsiella
pneumoniae

A recent study on adverse drug reports (ADRs) with SGLT2 inhibitors (dapagliflozin, canagliflozin, and empagliflozin) in
Spain over a period of 3.5-year showed increased reporting of
urogenital tract infections (32).
Although, candida colonization is mostly asymptomatic and
does not require treatment, Infectious Diseases Society of
America (IDSA) recommends performing urine culture and to
treat any positive urine culture prior to urological procedure
(3, 25). When indicated, oral fluconazole, 400 mg (6 mg/kg)
daily, OR Amphotericin B deoxycholate, 0.3–0.6 mg/kg daily
is considered to be drug of choice (3). However, the duration
of antifungal therapy required to achieve sterilization of urine
is not well-established and current practice varies from 48 h
to 3 weeks before stent exchange (25). Furthermore, several
days of antifungal agents may not be practically feasible
especially in situations where patient might require acute
urologic interventions, e.g., ureteral stent placement for stone or
obstruction.
Our case highlights a rare and unusual adverse event of
canagliflozin in patient with diabetes who underwent ureteric
stent placement. With increasing use of SGLT-2 inhibitors,
more patients will be at risk of urinary tract colonization with
candida, which might result in increased incidences of candida
colonization related complications (e.g., symptomatic candiduria
or candidemia following urologic surgery). Large comparative
studies are required to address the necessity of antifungal therapy
and its duration in preventing candidemia in patient with type 2
diabetes on SGLT-2 inhibitors undergoing urologic procedures.
We also recommend discontinuation of SGLT-2 inhibitors prior

and acidic urine pH are other known risk factors for urinary
candida colonization (6, 7, 16–21).
Urologic procedure like ureteral stent placement may lead
to bacterial (68–90%) and candidal (10–40%) colonization of
urinary tract and is attributed to formation of a biofilm (22–
25). Dariane et al. found candiduria to be frequently associated
with ureteral stent placement, most commonly due to C. albicans
(19–72%) followed by C. glabrata (15.6–49.4%) (25, 26). Two
cases of candidemia was reported in elderly patients following
ureteric stent placement for nephrolithiasis. Both patients had
a positive candidal urine cultures at the time of procedure,
prior broad-spectrum antibiotic use, and one of them was
diabetic (27). Two cases of candidemia following ureteroscopy
with stone manipulation was reported in patients with cirrhosis
who underwent ureteric stent placement for obstructing stone
and developed candidemia at the time of stent removal at 60
and 35 days (28). The mechanism of candidemia following
ureteroscopy or ureteral stenting is proposed to be direct
bloodstream seeding through microscopic lacerations in the
presence of increased intra-ureteral pressure during ureteroscopy
resulting in pyelovenous and pyelolymphatic reflux (25).
Our patient developed candidemia within 2 weeks following
ureteric stent placement while on SGLT-2 inhibitor, raising
concern about association of SGLT-2 inhibitor with increased
risk of candidemia following ureteric stent placement. SGLT-2
inhibitors result in glycosuria up to 70–120 g per day (29). This
pharmacologically-induced glycosuria may be implicated in the
increased urogenital candida colonization in patients on SGLT2
inhibitors compared to placebo (10–31 vs. 3–14%) (30, 31).
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urinary colonization is advised before performing any urological
procedures.

to non-emergent/elective urologic interventions in order to
decrease the colonization by candida, but more studies are
needed to establish the exact duration of drug discontinuation
required to result in appropriate urinary tract decolonization and
optimal time for reinitiation.

PATIENT CONSENT
Written informed consent was obtained from the participant for
publication of this case report.

CONCLUSION

AUTHOR CONTRIBUTIONS

In summary, candida colonization of ureteral stents is common
and can rarely lead to subsequent candidemia following urologic
procedures especially in presence of risk factors. Due to the
risk of urogenital candida infections in patients with diabetes
treated with SGLT-2 inhibitors, urine culture and treatment of

JH contributed in preparing the case presentation. RR and AJ
prepared the discussion of the manuscript. DA reviewed the
manuscript in detail.
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